(Albany, United States) As per DelveInsight’s assessment, globally, the Presbyopia pipeline constitutes 12+ key companies continuously working towards developing 12+ Presbyopia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Presbyopia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Presbyopia clinical trials studies, Presbyopia NDA approvals (if any), and product development activities comprising the technology, Presbyopia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

To explore more information on the latest breakthroughs in the Presbyopia Pipeline treatment landscape of the report, click here @ Presbyopia Pipeline Outlook

 

Key Takeaways from the Presbyopia Pipeline Report

• DelveInsight’s Presbyopia Pipeline analysis depicts a robust space with 12+ active players working to develop 12+ pipeline treatment therapies.
• The leading Presbyopia Companies working in the market include Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others
• Promising Presbyopia Pipeline Therapies in the various stages of development include 0.1% STN1013600 ophthalmic solution, UNR844-Cl, Phentolamine Opthalmic Solution 0.75%, Pilocarpine, EV06 Ophthalmic Solution, and others
• On May 2023, Santen Inc announced a study of phase 2 clinical trials for 0.3% STN1013600 ophthalmic solution. This is a Phase IIa study to assess efficacy and safety of STN1013600 ophthalmic solution (0.1%, and 0.3 %), twice daily when compared to Placebo in subjects diagnosed with presbyopia. This study will consist of a Screening Period of up to 15 days followed by a 2 Month Treatment Period. After the Treatment Period subjects will be followed for a one-month treatment free period.
• On March 2023, LinkoCare Life Sciences AB announced a study of phase X clinical trials for Intrastromal implantation of CorVision bioengineered corneal inlay for correction of presbyopia. This clinical investigation is a prospective, multicentre, non-comparative case series to assess safety and efficacy of CorVision® bioengineered corneal inlay for improving uncorrected near vision in presbyopic subjects.
• On March 2023, Allergan announced a study of phase 3 clinical trials for Pilocarpine HCl. Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating presbyopia compared to vehicle (placebo).
• On April 2023, Ocuphire Pharma Inc announced a study of phase 3 clinical trials for Phentolamine Opthalmic Solution 0.75%. To evaluate the safety and efficacy of Nyxol alone and with adjunctive low dose pilocarpine to improve distance-corrected near visual acuity (DCNVA) in subjects with presbyopia.

 

Presbyopia Overview

Presbyopia is a vision condition in which the shape of the crystalline lens of your eye changes. These changes make it difficult to focus on close objects. Presbyopia may seem to occur suddenly, but sight reduction occurs over several years. Presbyopia usually becomes noticeable in the early to mid-40s, but the reduction of your focus starts as early as childhood.

 

To explore more information on the latest breakthroughs in the Presbyopia Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight

 

Presbyopia Emerging Drugs Profile

• CSF-1: Orasis Pharmaceuticals
• UNR844-Cl: Novartis

 

Presbyopia Pipeline Therapeutics Assessment

There are approx. 12+ Presbyopia companies which are developing the therapies for Presbyopia. The Presbyopia companies which have their Presbyopia drug candidates in the most advanced stage, i.e. phase III include, Orasis Pharmaceuticals.

 

Request a sample and discover the recent advances in Presbyopia Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight

 

Presbyopia Drugs and Companies

• 0.1% STN1013600 ophthalmic solution: Santen Inc
• UNR844-Cl: Novartis Pharmaceuticals
• Phentolamine Opthalmic Solution 0.75%: Ocuphire Pharma Inc
• Pilocarpine HCl: Allergan
• EV06 Ophthalmic Solution: Encore Vision

 

Presbyopia Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Presbyopia Therapeutics Market include-

Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.

 

Dive deep into rich insights for drugs for Presbyopia Pipeline, click here for Presbyopia Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight

 

Scope of the Presbyopia Pipeline Report

• Coverage- Global
• Presbyopia Companies- Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.
• Presbyopia Pipeline Therapies- 0.1% STN1013600 ophthalmic solution, UNR844-Cl, Phentolamine Opthalmic Solution 0.75%, Pilocarpine, EV06 Ophthalmic Solution, and others.
• Presbyopia Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Presbyopia Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Presbyopia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Presbyopia – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. CSF-1: Orasis Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. UNR844-Cl: Novartis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Presbyopia Key Companies
21. Presbyopia Key Products
22. Presbyopia- Unmet Needs
23. Presbyopia- Market Drivers and Barriers
24. Presbyopia- Future Perspectives and Conclusion
25. Presbyopia Analyst Views
26. Presbyopia Key Companies
27. Appendix

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services